Esperion Therapeutis.Inc. sell nvestor
Start price
18.03.23
/
50%
€1.46
Target price
18.03.24
€1.00
Performance (%)
-1.58%
End price
01.04.23
€1.43
Summary
This prediction ended on 01.04.23 with a price of €1.43. With a performance of -1.58%, the SELL prediction by nvestor was trending in the right direction. nvestor has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | 8.070% | 8.070% | 66.538% |
| iShares Core DAX® | 2.112% | -0.367% | 13.466% |
| iShares Nasdaq 100 | -2.197% | -3.794% | 38.426% |
| iShares Nikkei 225® | -1.555% | -7.320% | 18.451% |
| iShares S&P 500 | -0.472% | -2.078% | 27.488% |
Comments by nvestor for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.